St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
NCT Number: NCT02399956
While the majority of women in the general population can breastfeed successfully, the investigators have limited knowledge about the correlates and sequelae of lactation success among women treated for pediatric malignancies. Childhood cancer treatments are known to cause late effects that frequently involve the endocrine system. Because normal lactation is dependent upon interplay of multiple endocrine factors, the investigators anticipate more breastfeeding difficulties in survivors that have diabetes, growth hormone deficiencies, thyroid disorders and obesity. In order to more fully inform clinicians and female survivors, the study of the burden of lactation failure is needed to begin to address the impact of pediatric cancer therapy on lactation success/failure and to examine the association of specific endocrine disorders on lactation outcomes.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Memphis, Tennessee, 38105, United States
Participants will complete a cross-sectional survey. Responses will be compared with a national sample of healthy women from Project First (Infant Feeding Practices Survey II).
Primary Objective:
Secondary Objective:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
Other names: Questionnaire
Time frame: Once, at enrollment (Day 1)
Time frame: Once, at enrollment (Day 1)
Years since diagnosis will equal the years since diagnosis prior to first pregnancy resulting in a live birth.
Time frame: Once, at enrollment (Day 1)
Time frame: Once, at enrollment (Day 1)
Includes chest and/or brain surgery.
Time frame: Once, at enrollment (Day 1)
Growth hormone deficiency indicated by low IGF-1
Time frame: Once, at enrollment (Day 1)
Hypothyroidism, primary or central, measured by TSH level.
Time frame: Once, at enrollment (Day 1)
Time frame: Once, at enrollment (Day 1)
Obesity (BMI) prior to pregnancy.
Time frame: Once, at enrollment (Day 1)
Breastfeeding outcomes (intention, initiation, and duration/weaning) will be determined by self-report, and dichotomized for analysis. Intention is defined as a mother's specific plan to breastfeed her infant prior to birth (yes/no); initiation is defined as ever having started breastfeeding (yes/no); duration is defined as at least 6 months of breastfeeding (yes/no); and weaning is defined as breastfeeding cessation after 1 year (yes/no).
Data from survivors will be compared with a national sample of healthy women (n=2,000) who responded to the Project First survey (2009). The Infant Feeding Practices Survey II (Project First) is a longitudinal study developed by the Food and Drug Administration and the Centers for Disease Control and Prevention.
St. Jude Children's Research Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06704243
Cancer, Hematologic Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT05131815
Astrocytoma, Behavior
Los Angeles, California, United States
View Trial DetailsNCT04896580
Behavior, Breast Cancer
Los Angeles, California, United States
View Trial DetailsNCT00179868
Cancer, Hematologic Diseases
Chicago, Illinois, United States
View Trial Details